How do the two forms differ?

The supplied material identifies CJC-1295 as a modified synthetic GHRH(1-29) analogue. It distinguishes an albumin-binding DAC variant from a no-DAC form, also called Modified GRF 1-29; the latter is reported to have a much shorter action period.

What did the human study measure?

The cited human study material reports changes in GH and IGF-I after administration. It does not provide large, long-term human trials demonstrating muscle-gain or fat-loss outcomes.

Is CJC-1295 FDA approved?

Not according to the supplied record. It identifies CJC-1295 as not FDA approved and describes a discontinued Phase II investigational program. The dated category and PCAC statements in that record should be checked against official FDA materials.

What are the key evidence limits?

The provided material supports short-term pharmacodynamic findings, but leaves long-term safety and practical clinical benefit unresolved. Reported muscle-gain and fat-loss interests are not established outcomes in the supplied evidence.

Which safety issues are reported in the source?

The source lists injection-site reactions, flushing, headache, water retention and dizziness, with possible histamine release in sensitive people. It also flags theoretical concern where higher GH or IGF-I activity may be undesirable, including cancer contexts, and notes immunogenicity as a risk. These source-reported items do not establish their frequency or long-term incidence.

Hormon wzrostu Badania kliniczne - trwają badania u ludzi

Modified GRF (1-29)

Znany też jako: CJC-1295 without DAC, CJC-1295 No DAC, Tetrasubstituted GRF (1-29)

W skrócie

Zbiór danych PeptiGuide · przegląd sie 2026

Czym jest

A GHRH analogue reported in albumin-binding DAC and shorter no-DAC forms.

Status

Badania kliniczne

Poziom dowodów: badania z udziałem ludzi

Typowa dawka

The community-reported amount appears in the dosing row.

Subcutaneous route

Badany pod kątem

The source lists growth hormone optimization, muscle gain, and fat loss as research interests; it does not establish those benefits.

Postęp badań

PrePrzedkliniczne
IFaza I
IIFaza II
IIIFaza III
IVFaza IV
FDAZatwierdzone przez FDA

Nie dotyczy - Wczesne dane u ludzi z istotnymi ograniczeniami

Użyj narzędzi

Prostym językiem

Synthetic GHRH(1-29) analogue reported in DAC and no-DAC forms.
DAC is described as albumin-binding and longer-lived; no-DAC is also called Modified GRF 1-29.
Supplied human evidence concerns GH and IGF-I pharmacodynamics, not established body-composition outcomes.
The source says development by ConjuChem ended after Phase II and describes the compound as a research chemical rather than an approved drug.

Jak prawdopodobnie działa

CJC-1295 is described as a synthetic modification of GHRH(1-29). The supplied material says it activates GHRH receptors on pituitary somatotrophs, increasing pituitary GH release, with hepatic IGF-I production following the GH rise. Native GHRH is described as being degraded within minutes. In the DAC variant, a reactive moiety is reported to attach covalently to circulating albumin after injection, reducing breakdown. The no-DAC form, Modified GRF 1-29, lacks this attachment and is reported to act for about 30 minutes. The described pathway depends on residual pituitary capacity for GH production.

Co pokazują badania

Na jakim etapie są badania

Evidence reviewed for CJC-1295 separates pharmacokinetic findings from clinical outcomes. The DAC form is described as having a half-life of roughly 6 to 8 days, whereas the non-DAC form is described as acting for about 30 minutes. In the 2006 randomized ascending-dose study, one injection was associated with GH elevation lasting at least 6 days and IGF-I elevation for 9 to 11 days; repeat dosing produced cumulative hormone effects. A mouse experiment reported restored growth with daily exposure. The material does not provide large, long-term human trials demonstrating fat loss or muscle gain. Development stopped after Phase II, and the reported trial death was attributed by the treating physician to pre-existing coronary disease, an attribution not independently confirmed.

Co pokazują

✓ Badania z udziałem ludzi

Wczesne dane u ludzi z istotnymi ograniczeniami

△ Ograniczenia

Protokoły badawcze opisują badania i nie są rekomendacjami dawkowania.

Podsumowanie: The source characterizes the program as investigational and Phase II-discontinued. It reports Category 2 removal in September 2024 for PCAC review, a Category 1 reclassification expectation on April 15, 2026, and PCAC review on July 23–24, 2026; it says Category 2 remains pending a formal FDA rule. Not FDA Approved

Typowe dawkowanie

SpołecznośćZbiór danych społeczności

100 mcg

daily (no DAC) or 2 mg weekly (with DAC)

100 mcgpełny obserwowany zakres300 mcg

The source describes daily use for no-DAC and a longer-lived DAC form. It also mentions co-use with a GHRP such as Ipamorelin. This community report is informational rather than medical advice.

Dawkowanie badawcze

Protokoły badawczeTrwają badania u ludzi - protokoły są specyficzne dla badań

Dawki obserwowane w badaniach

CJC-1295 DAC: 1-2mg weekly

Research Literature - Observed in studies

Protokoły badawcze opisują badania i nie są rekomendacjami dawkowania.

Czas trwania: 8-12 weeks
Podanie: Subcutaneous injection

Timing i podanie

Najlepsza pora

Before bed

1-2 times per week

Zalecenia żywieniowe

Take on empty stomach

Dlaczego taki timing?

For DAC, the source gives an approximately 8-day half-life, so it treats clock time as less material; it nevertheless associates evening use with natural GH patterns.

Możliwe skutki uboczne

Nie każdy ich doświadcza. Indywidualne reakcje zależą od dawki, czasu trwania i czynników osobistych.

Generally well-tolerated
Injection site reactions
Facial flushing
Headache
Water retention
Dizziness
Possible histamine release
IGF-I/GH-related concerns for people with cancer
Risk of immunogenicity

Nie każdy doświadcza skutków ubocznych, a nasilenie może zależeć od kontekstu, czystości, drogi podania i indywidualnych czynników zdrowotnych.

Źródła

PubMed ClinicalTrials.gov FDA.gov

Najczęstsze pytania

Sekwencja

H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

Jeden otwarty zbiór danych

Każdy fakt na tej stronie - dawki, skutki uboczne, referencje - pochodzi z tego samego zbioru danych PeptiGuide, który zasila Tracker, Porównywarkę i Lab.

Przeglądaj zbiór danych

Zapisz na mojej liście Aktualizacje o Modified GRF (1‑29)

Materiał edukacyjny, nie porada medyczna. Porozmawiaj z lekarzem, zanim podejmiesz działania.

Dyskusja społeczności

Komentarze są moderowane przed publikacją. Trzymajmy się dowodów.

Modified GRF (1-29)

Prostym językiemProstym językiem

Jak prawdopodobnie działaJak prawdopodobnie działa

Co pokazują badaniaCo pokazują badania

Typowe dawkowanie

Dawkowanie badawcze

Timing i podanieTiming i podanie

Możliwe skutki uboczneMożliwe skutki uboczne

ŹródłaŹródła

Najczęstsze pytaniaNajczęstsze pytania